The Role of TRIM23 in Autophagy Mediated Antiviral Defenses
TRIM23 在自噬介导的抗病毒防御中的作用
基本信息
- 批准号:10394983
- 负责人:
- 金额:$ 44.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:Amino Acid MotifsAntiviral AgentsAntiviral ResponseAutophagocytosisAutophagosomeBindingBiochemicalBiologicalBiological ProcessC-terminalCell Culture SystemCellsCytokine SignalingDataDefense MechanismsDevelopmentFamily memberFoundationsGene TargetingGuanosine TriphosphateGuanosine Triphosphate PhosphohydrolasesHerpesvirus 1Host DefenseHost resistanceHydrolysisImmuneImmune signalingImmunityIn VitroInfectionInterferonsKnockout MiceKnowledgeLaboratoriesLinkLysosomesMediatingMicrobiologyMolecularN-terminalNatural ImmunityNatureNerve DegenerationOrganellesPathogenesisPathway interactionsPhosphorylationPhosphotransferasesPhysiologicalPlayPolyubiquitinProcessProtein FamilyProteinsRegulationRoleSeriesTBK1 geneTRIM MotifTestingUbiquitin CUbiquitinationViralViral PathogenesisVirusVirus DiseasesVirus ReplicationWild Type MouseWorkantimicrobialantiviral drug developmentantiviral immunitycell typecytokinedesignin vivoinsightmouse modelmutantpathogenpathogenic virusrational designreceptorresponseubiquitin-protein ligaseupstream kinaseviral resistance
项目摘要
PROJECT SUMMARY
Autophagy, the process by which cells dispose of cellular contents, has been
increasingly appreciated as an important pathway in antiviral host defenses. Intriguingly, recent
studies demonstrated that autophagy and the antiviral type I IFN response are intricately
connected, and several molecules known to play key roles in IFN-mediated immunity are also
important regulators of autophagy. Among these molecules with dual roles in autophagy and
IFN-mediated immunity are several TRIM (tripartite motif) protein family members. However,
whereas the molecular mechanisms by which TRIM proteins act as antiviral restriction factors or
regulate IFN responses have been well characterized, our knowledge about the role of TRIM
proteins in autophagy in response to viral infection is still rudimentary.
The proposed study builds on a recent discovery by the Gack laboratory that identified
TRIM23 as a critical regulator of autophagy-mediated host defense against a broad range of
viruses. TRIM23 interacts with and activates the innate immune molecule TBK1, promoting
TBK1-mediated phosphorylation of the selective autophagy receptor p62, which ultimately
triggers viral clearance and host resistance. Mechanistically, the N-terminal RING E3 ligase of
TRIM23 induces atypical non-degradative K27-linked auto-ubiquitination of the C-terminal ARF
GTPase domain, which is unique to TRIM23. ARF ubiquitination results in enhanced activity of
TRIM23 to hydrolyze GTP, activate TBK1, and mediate virus resistance. TRIM23 depletion or
gene-targeting in various cell types showed that TRIM23-mediated autophagy confers antiviral
activity against several viruses including HSV-1.
Using molecular, biochemical, cell biological and structural approaches combined with
virus infection studies, we will define in precise detail how TRIM23 mediates autophagy during
viral infection. This study will yield insight into the mechanisms of TRIM23 activation by
upstream regulators during viral infection (Aim 1). We will further determine the molecular
details of how TRIM23 activates TBK1 and the role the enzymatic activities of TRIM23 – E3
ligase and GTPase – play in TBK1 activation. Finally, we will determine the physiological
relevance of TRIM23 for antiviral host resistance and viral pathogenesis using in vitro cell
culture systems and infection studies in TRIM23 knockout mice (Aim 2). Our studies will provide
a molecular understanding of a key pathway in the autophagy-mediated host defense, which
may guide the rational design of new antivirals.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michaela Ulrike Gack其他文献
Michaela Ulrike Gack的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michaela Ulrike Gack', 18)}}的其他基金
Role of ADAM9 in viral RNA sensing and antiviral innate immunity
ADAM9 在病毒 RNA 传感和抗病毒先天免疫中的作用
- 批准号:
10753041 - 财政年份:2023
- 资助金额:
$ 44.52万 - 项目类别:
Defining the viral PTMome: Towards the development of novel antiviral approaches
定义病毒 PTMome:致力于开发新型抗病毒方法
- 批准号:
10490866 - 财政年份:2021
- 资助金额:
$ 44.52万 - 项目类别:
Defining the viral PTMome: Towards the development of novel antiviral approaches
定义病毒 PTMome:致力于开发新型抗病毒方法
- 批准号:
10662495 - 财政年份:2021
- 资助金额:
$ 44.52万 - 项目类别:
Novel Role for Host Immunostimulatory RNA in Antiviral Immune Defense
宿主免疫刺激 RNA 在抗病毒免疫防御中的新作用
- 批准号:
10338487 - 财政年份:2021
- 资助金额:
$ 44.52万 - 项目类别:
Novel Role for Host Immunostimulatory RNA in Antiviral Immune Defense
宿主免疫刺激 RNA 在抗病毒免疫防御中的新作用
- 批准号:
10492729 - 财政年份:2021
- 资助金额:
$ 44.52万 - 项目类别:
Novel Role for Host Immunostimulatory RNA in Antiviral Immune Defense
宿主免疫刺激 RNA 在抗病毒免疫防御中的新作用
- 批准号:
10676843 - 财政年份:2021
- 资助金额:
$ 44.52万 - 项目类别:
Defining the viral PTMome: Towards the development of novel antiviral approaches
定义病毒 PTMome:致力于开发新型抗病毒方法
- 批准号:
10261712 - 财政年份:2021
- 资助金额:
$ 44.52万 - 项目类别:
The Role of TRIM23 in Autophagy Mediated Antiviral Defenses
TRIM23 在自噬介导的抗病毒防御中的作用
- 批准号:
10623146 - 财政年份:2020
- 资助金额:
$ 44.52万 - 项目类别:
The Role of TRIM23 in Autophagy Mediated Antiviral Defenses
TRIM23 在自噬介导的抗病毒防御中的作用
- 批准号:
10353335 - 财政年份:2020
- 资助金额:
$ 44.52万 - 项目类别:
EBV infection control by RNA surveillance
通过 RNA 监测控制 EBV 感染
- 批准号:
10283975 - 财政年份:2019
- 资助金额:
$ 44.52万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 44.52万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 44.52万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 44.52万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 44.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 44.52万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 44.52万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 44.52万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 44.52万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 44.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 44.52万 - 项目类别:














{{item.name}}会员




